Search

SWG Educational Activities

During the annual meeting of EHA, a scientific session was organized: “Mesenchymal stromal cells: guardians of tissue homeostasis”.

Read more

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.

Read more

Chairs and Members

Chair (2022–2025 term)Philipp Staber, Medical University Vienna (Austria)

Co-chair (2022–2025 term)Caroline Heckman, FIMM, Helsinki (Finland)

SWG Steering Committee members (2022–2025 term)
Jean-Pierre Bourquin, Universitäts-Kinderspital Zürich (Switzerland)
Kirsten Grønbæk, University of Copenhagen (Denmark)
Eva Hellström Lindberg, Karolinska Institutet, Stockholm (Sweden)
Ulrich Jäger, Medical University Vienna (Austria)
Luca Malcovati,…

Read more

Publications

Robust scoring of selective drug responses method in Nature ProtocolsSWG members have published a method in Nature Protocols that allows robust scoring of selective drug responses for patient-tailored therapy selection.

Read more

Publications

For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.

Read more

Chairs and Members

Chair:

Marc H. G. P. Raaijmakers, M. D. , Ph. D.

Read more

Chairs and Members

ChairPieter Sonneveld (Rotterdam, The Netherlands)

Members
Niels Abildgaard (Odense, Denmark)
Meral Beksac (Ankara, Turkey)
Luca Berthamini (Rotterdam, Netherlands)
Lenka Bešše, Brno (Czech Republic)
Dr Bila (Belgrade, Serbia)
Nicole Brolli (Milano, Italy)
Sara Bringhen (Turin, Italy)
Mario Boccadoro (Turin, Italy)
Anna Maria Brioli (Bologna, Italy)
Annemiek Broyl (Rotterdam, Netherlands)—also Chair of Young…

Read more

SWG Educational Activities

In 2021, the SWG on Multiple Myeloma contributed a major part of the ESMO-EHA guidelines for multiple myeloma. The rapid changes of the treatment landscape for this disease require an adaptation of the guidelines.

Read more